Darolutamide
Brand name: Nubeqa
Rank #95 of 500 drugs by total cost
$188.8M
Total Cost
14,375
Total Claims
$188.8M
Total Cost
472
Prescribers
$13K
Cost per Claim
851
Beneficiaries
14,508
30-Day Fills
$400K
Avg Cost/Provider
30
Avg Claims/Provider
About Darolutamide
Darolutamide (sold as Nubeqa) was prescribed 14,375 times by 472 Medicare Part D providers in 2023, costing the program $188.8M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 92 | Denosumab (Prolia) | $199.4M | 114,710 |
| 93 | Ticagrelor (Brilinta) | $195.8M | 293,897 |
| 94 | Lurasidone Hcl (Latuda) | $190.9M | 254,237 |
| 95 | Darolutamide (Nubeqa) | $188.8M | 14,375 |
| 96 | Fluticasone Propionate (Fluticasone Propionate) | $187.5M | 5,343,836 |
| 97 | Hydrocodone/Acetaminophen (Hydrocodone-Acetaminophen) | $185.6M | 8,496,609 |
| 98 | Vibegron (Gemtesa) | $185.2M | 283,953 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology